Alzamend Neuro receives Study May Proceed letter from FDA for Alzheimer’s study

Alzamend Neuro announced receipt of a "Study May Proceed" letter from the FDA for a phase I/IIA clinical trial under its Investigational New Drug, or IND, application for an immunotherapy to treat mild to moderate dementia of the Alzheimer’s type.